28-Mar-2024
No headlines found.
Globe Newswire (Tue, 26-Mar 8:30 AM ET)
Globe Newswire (Wed, 20-Mar 8:00 AM ET)
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
Globe Newswire (Fri, 8-Mar 4:05 PM ET)
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globe Newswire (Mon, 4-Mar 8:30 AM ET)
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Globe Newswire (Tue, 30-Jan 8:30 AM ET)
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
Globe Newswire (Wed, 3-Jan 8:00 AM ET)
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Entera Bio Ltd. - trades on the NASDAQ stock market under the symbol ENTX.
As of March 28, 2024, ENTX stock price climbed to $1.67 with 122,836 million shares trading.
ENTX has a beta of 1.00, meaning it tends to be more sensitive to market movements. ENTX has a correlation of 0.02 to the broad based SPY ETF.
ENTX has a market cap of $59.25 million. This is considered a Micro Cap stock.
In the last 3 years, ENTX stock traded as high as $8.68 and as low as $.47.
ENTX has outperformed the market in the last year with a price return of +62.1% while the SPY ETF gained +33.6%. ENTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +165.1% and +15.2%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
ENTX support price is $1.39 and resistance is $1.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENTX stock will trade within this expected range on the day.